Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced participation in two investor conferences in March 2023. The company will host a fireside chat at Cowen's 43rd Annual Health Care Conference on March 7 at 9:50 a.m. ET, and at the Barclays Global Healthcare Conference on March 16 at 9:00 a.m. ET. Live webcasts of these discussions will be available on the company's website, with archived replays accessible for 90 days post-event. Bicycle Therapeutics specializes in developing a new class of therapeutics using its proprietary Bicycle technology, targeting underserved diseases with high-affinity and selectivity.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in March:

• Cowen’s 43^rd Annual Health Care Conference on Tuesday, March 7, 2023; fireside chat at 9:50 a.m. ET
• Barclays Global Healthcare Conference on Thursday, March 16; fireside chat at 9:00 a.m. ET

Live webcasts of the fireside chats will be accessible in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available for 90 days following the fireside chat dates.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005147/en/

Investors:

David Borah, CFA

SVP, Capital Markets & Corporate Communications

david.borah@bicycletx.com

617-203-8300

Media:

Argot Partners

Sarah Sutton

bicycle@argotpartners.com

212-600-1902

Source: Bicycle Therapeutics

FAQ

When is Bicycle Therapeutics participating in investor conferences?

Bicycle Therapeutics will participate in the Cowen's 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. ET and the Barclays Global Healthcare Conference on March 16, 2023, at 9:00 a.m. ET.

Where can I watch the live webcasts for Bicycle Therapeutics' conferences?

The live webcasts for Bicycle Therapeutics' conferences can be accessed on their website in the Investors & Media section.

What is the focus of Bicycle Therapeutics' drug development?

Bicycle Therapeutics focuses on developing a novel class of medicines using their proprietary Bicycle technology to target diseases that are underserved by existing therapeutics.

What products is Bicycle Therapeutics currently evaluating?

Bicycle Therapeutics is evaluating BT5528, BT8009, and BT7480 in Phase I/II trials, as well as BT1718 in a Phase I/IIa trial.

How long will the archived replays of Bicycle Therapeutics' conferences be available?

Archived replays of the webcasts will be available for 90 days following the dates of the fireside chats.